"We reserve the right to surprise", page-34

Exciting times ahead!!!

Final Phase 2 data read out delay due to PATIENTS LIVING LONGER .....

8 clinical trials

5 data read out in the next 6 months

Phase 3 trial in GBM started in Jan 2021 - fully funded

Kazia starting NDA application

US$30 million CASH

Kazia Licenses Rights to Cantrixil to Oasmia for US$4 million up front, and development milestones worth up to US$42 million and double-digit sales royalties.

Kazia Licenses Rights to Paxalisib in Greater China to Simcere for US$ 11 million and milestone payments of up to US$ 281 million plus mid-teen percentage royalties on commercial sales for GBM only

Kazia Licenses Rights to Paxalisib outside Greater China for US $X billion and double-digit sales royalties in GBM only

Kazia Licenses Rights to Paxalisib for US $X billion and double-digit sales royalties outside GBM